Skip to main content
An official website of the United States government

autologous anti-CD19 AbTCR-expressing T lymphocytes EB103

A preparation of autologous T lymphocytes transduced with a lentiviral vector encoding an antibody-T-cell-receptor (AbTCR) composed of a CD19-binding domain derived from an antibody fragment antigen binding (Fab) region and an effector domain derived from human gamma/delta TCR, and a co-stimulatory molecule composed of a CD19-binding domain derived from a single-chain variable fragment (scFv) and a co-stimulatory domain derived from a human co-stimulatory receptor, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous anti-CD19 AbTCR-expressing T lymphocytes EB103, both the AbTCR moiety and the co-stimulatory molecule recognize and bind to CD-19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.
Synonym:autologous anti-CD19 AbTCR-expressing T cells EB103
autologous anti-CD19 antibody redirected T cells with endogenous modular immune signaling EB103
autologous CD19-redirected ARTEMIS T cells EB103
Code name:EB 103
EB-103
EB103
Search NCI's Drug Dictionary